Rebecca A Previs
Adjunct Assistant Professor in the Department of Obstetrics and Gynecology
Current Research Interests
Immune microenviroment in gynecologic malignancies, novel therapies for ovarian and uterine cancer, PARP inhibition in uterine cancer, molecular testing of gynecologic malignancies, early Phase clinical trials
Current Appointments & Affiliations
- Adjunct Assistant Professor in the Department of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 2022
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2018
Contact Information
- Division of Gynecologic Oncolo, DUMC Box 3079, Durham, NC 27710
-
rebecca.previs@duke.edu
(919) 684-8111
- Background
-
Education, Training, & Certifications
- Fellow, Gynecologic Oncology, University of Texas MD Anderson Cancer Center 2013 - 2017
- Residency, Obstetrics And Gynecology, Duke University School of Medicine 2009 - 2013
- M.D., University of Virginia School of Medicine 2009
-
Medical Licensure
- 2017-00965. North Carolina. 2023
-
Previous Appointments & Affiliations
- Assistant Professor of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 2021 - 2022
- Assistant Professor of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 2017 - 2020
-
Leadership & Clinical Positions at Duke
-
Phase I Gynecologic Oncology disease site champion 2017 to present
Department of OB/Gynecology Enhanced Recovery After Surgery (ERAS) - Division champion - 2018 to present
Duke Center for Brain and Spine Metastasis Gynecologic Oncology Champion - 2019 to present
Center for Cancer Immunology disease site champion - 2019 to present
EMPOWER leadership - 2019 to present
DCI Community Outreach, Engagement, and Equity Steering Committee 2021 to present
DCI Rural Disparities Subgroup 2022 to present
DCI Patient Advisory Council for Inclusive Research 2022 to present
DCI Focus Group on Adoptive T-cell Therapies 2022 to present
Department of OB/Gynecology Enhanced Recovery After Surgery (ERAS) - Co-Leader - 2018 to 2020
2018 Duke course on Leadership Development for Researchers (LEADER)
-
Phase I Gynecologic Oncology disease site champion 2017 to present
-
Academic Positions Outside Duke
- Translational Science Committee, NRG Oncology. 2022 - 2023
- Program Committee, Society of Gynecologic Oncologists. 2020 - 2021
- GOG-Foundation Communications Committee, GOG-Foundation. 2019 - 2022
- Developmental Therapeutics/Phase 1 General Member, NRG Oncology. 2019 - 2022
- Communications Committee, NRG Oncology. 2018 - 2022
- New Investigator's Committee, NRG Oncology. 2017 - 2020
- Recognition
-
In the News
-
APR 8, 2022 -
DEC 1, 2021 -
MAY 3, 2019 -
DEC 26, 2018 Duke Cancer Institute -
OCT 10, 2018 Duke Cancer Institute -
SEP 20, 2018 Duke Cancer Institute -
JAN 17, 2018 Duke OB/GYN Department
-
-
Awards & Honors
- Duke Ob/Gyn Excellence in Medical Student Teaching Commendation 2021. Department of OB/Gyn. 2021
- Duke Ob/Gyn Excellence in Medical Student Teaching Commendation 2020. Department of OB/Gyn. 2020
- GOG Foundation New Investigator Award Program. GOG Foundation Education/Mentoring Committee in collaboration with the NRG Oncology New Investigator Committee and the Society of Gynecologic Oncology (SGO). May 2, 2019
- The Diane Denson Tobola Fellowship in Ovarian Cancer Research. The University of Texas MD Anderson Cancer Center. 2016
- The Linda K. Manning Fellowship in Ovarian Cancer. The University of Texas MD Anderson Cancer Center. 2015
- Best resident oral presentation. Mid-Atlantic Gynecologic Oncology Society. 2012
- Speaker, 97th Annual Proclamation Night . University of Richmond. 2012
- C. Richmond Bowman Scholarship Award. University of Virginia School of Medicine. 2009
- Gold Humanism Honor Society. University of Virginia School of Medicine. 2008
- Speaker, 175th Baccalaureate Service during Commencement. University of Richmond. 2008
- Oldham Scholar. University of Richmond. 2005
- Speaker, 2005 Arts & Sciences Honors Convocation . University of Richmond. 2005
- Research
-
Selected Grants
- A Role of Multilevel Healthcare Access Dimensions in Ovarian Cancer Disparities awarded by National Institutes of Health 2019 - 2024
- Novel see and treat strategies for cervical cancer prevention in low-resource settings awarded by National Institutes of Health 2019 - 2024
- Use of an oncolytic adenovirus to promote anti-tumor T-cell responses in ovarian cancer awarded by Foundation for Women's Cancer 2022 - 2023
- Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer awarded by National Institutes of Health 2014 - 2023
- Adrenergic signaling inhibition to enhance the immunogenicity of the ovarian tumor microenvironment prior to PD-1 checkpoint therapy awarded by Ponce Health Sciences University 2020 - 2022
- Molecular classification of endometrial advanced stage cancers and association with survival outcomes: Ancillary analysis of GOG-0258 awarded by American Association of Obstetricians and Gynecologists Foundation 2021 - 2022
- Are ESR1 mutations associated with shorter progression free survival in copy number-low endometrial adenocarcinomas? awarded by Foundation for Women's Cancer 2020 - 2022
- Immune modulation of CaMKK2 in the ovarian tumor microenvironment awarded by American Association of Obstetricians and Gynecologists Foundation 2019 - 2020
- Evaluation of homologous recombination deficiency in uterine serous cancer awarded by Myriad Genetics, Inc. 2018 - 2019
- Janet Burros Ovarian Cancer Repository awarded by Cancer Data Initiative 2018 - 2019
-
Fellowships, Supported Research, & Other Grants
- Prospective randomized trial of streamlined genetic education and testing for ovarian, fallopian and peritoneal cancer patients awarded by Gray Foundation 2019 - 2021
- Exploring the immune contexture of molecularly characterized uterine cancers awarded by Goldman Sachs Philanthropy Fund/Emerson Collective Fund 2019 - 2022
- Janet Burros Ovarian Cancer Repository in collaboration with the Cancer Data Initiative awarded by Janet Burros Memorial Foundation 2018
- Molecular classification of medically managed endometrial tumors awarded by Charles Hammond Research Fund 2018
- T32 Training Grant awarded by NCI-DHHS-NIH 2013 - 2015
-
External Relationships
- Myriad Genetics, Inc
- Natera
- PeerView
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Akinyemiju T, Chen Q, Wilson LE, Previs RA, Joshi A, Liang M, Pisu M, Ward KC, Berchuck A, Schymura MJ, Huang B. Healthcare Access Domains Mediate Racial Disparities in Ovarian Cancer Treatment Quality in a US Patient Cohort: A Structural Equation Modelling Analysis. Cancer Epidemiol Biomarkers Prev. 2023 Jan 9;32(1):74–81.Full Text Link to Item
-
Albright BB, Wignall E, Bentley RC, Havrilesky LJ, Previs RA, Strickland KC. BAP1 Tumor Predisposition Syndrome Presenting as a Recurrent Ovarian Sex Cord-Stromal Tumor. Int J Gynecol Pathol. 2023 Jan 1;42(1):83–88.Full Text Link to Item
-
Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2022 Dec 5;JCO2200830.Full Text Link to Item
-
Anyanwu MC, Ohamadike O, Wilson LE, Meernik C, Huang B, Pisu M, Liang M, Previs RA, Joshi A, Ward KC, Tucker T, Schymura MJ, Berchuck A, Akinyemiju T. Race, Affordability and Utilization of Supportive Care in Ovarian Cancer Patients. J Pain Symptom Manage. 2022 Dec;64(6):537–545.Full Text Link to Item
-
Aquino-Acevedo AN, Knochenhauer H, Castillo-Ocampo Y, Ortiz-León M, Rivera-López YA, Morales-López C, Cruz-Robles ME, Hernández-Cordero ER, Russell S, Whitaker R, Bonilla-Claudio M, Chen D-T, Dutil J, Gaillard SL, Yi JS, Previs RA, Armaiz-Pena GN. Stress hormones are associated with inflammatory cytokines and attenuation of T-cell function in the ascites from patients with high grade serous ovarian cancer. Brain Behav Immun Health. 2022 Dec;26:100558.Full Text Link to Item
-
Montes de Oca MK, Wilson LE, Previs RA, Gupta A, Joshi A, Huang B, Pisu M, Liang M, Ward KC, Schymura MJ, Berchuck A, Akinyemiju TF. Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study. J Natl Compr Canc Netw. 2022 Nov;20(11):1255-1266.e11.Full Text Link to Item
-
Wong J, Gonzalez R, Albright B, Hayes T, Swartz A, Havrilesky LJ, Lee PS, Previs RA. Telemedicine and gynecologic oncology: caring for patients remotely during a global pandemic. Ajog Glob Rep. 2022 Nov;2(4):100124.Full Text Link to Item
-
Bose S, Yao H, Huang Q, Whitaker R, Kontos CD, Previs RA, Shen X. Using genetically encoded fluorescent biosensors to interrogate ovarian cancer metabolism. J Ovarian Res. 2022 Oct 20;15(1):114.Full Text Link to Item
-
Russell S, Lim F, Peters PN, Wardell SE, Whitaker R, Chang C-Y, Previs RA, McDonnell DP. Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer. Cancers (Basel). 2022 Aug 30;14(17).Full Text Open Access Copy Link to Item
-
Modesitt SC, Havrilesky LJ, Previs RA, Alejandro Rauh-Hain J, Michael Straughn J, Bakkum-Gamez JN, Fuh KC, Cohn DE. Ridiculously good writing: How to write like a pro and publish like a boss. Gynecol Oncol Rep. 2022 Aug;42:101024.Full Text Link to Item
-
Akinyemiju TF, Wilson LE, Diaz N, Gupta A, Huang B, Pisu M, Deveaux A, Liang M, Previs RA, Moss HA, Joshi A, Ward KC, Schymura MJ, Berchuck A, Potosky AL. Associations of Healthcare Affordability, Availability, and Accessibility with Quality Treatment Metrics in Patients with Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1383–1393.Full Text Link to Item
-
Bose S, Huang Q, Ma Y, Wang L, Rivera GO, Ouyang Y, Whitaker R, Gibson RA, Kontos CD, Berchuck A, Previs RA, Shen X. G6PD inhibition sensitizes ovarian cancer cells to oxidative stress in the metastatic omental microenvironment. Cell Rep. 2022 Jun 28;39(13):111012.Full Text Link to Item
-
Goins EC, Weber JM, Truong T, Moss HA, Previs RA, Davidson BA, Havrilesky LJ. Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database. Gynecol Oncol. 2022 May;165(2):309–316.Full Text Link to Item
-
Huang AB, Wu J, Chen L, Albright BB, Previs RA, Moss HA, Davidson BA, Havrilesky LJ, Melamed A, Wright JD. Neoadjuvant chemotherapy for advanced stage endometrial cancer: A systematic review. Gynecol Oncol Rep. 2021 Nov;38:100887.Full Text Link to Item
-
Meljen VT, Mittenzwei R, Wong J, Puechl A, Whitaker R, Broadwater G, Hall AH, Bean SM, Bentley RC, Elvin JA, Berchuck A, Previs RA, Strickland KC. Endometrial Adenocarcinomas With No Specific Molecular Profile: Morphologic Features and Molecular Alterations of "Copy-number Low" Tumors. Int J Gynecol Pathol. 2021 Nov 1;40(6):587–596.Full Text Link to Item
-
Albright BB, Monuszko KA, Kaplan SJ, Davidson BA, Moss HA, Huang AB, Melamed A, Wright JD, Havrilesky LJ, Previs RA. Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2021 Sep;225(3):237.e1-237.e24.Full Text Link to Item
-
Wright JD, Huang Y, Melamed A, Albright BB, Hillyer GC, Previs R, Hershman MSDL. Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer. Gynecol Oncol. 2021 Sep;162(3):599–605.Full Text Link to Item
-
Mueller JL, Morhard R, DeSoto M, Chelales E, Yang J, Nief C, Crouch B, Everitt J, Previs R, Katz D, Ramanujam N. Optimizing ethyl cellulose-ethanol delivery towards enabling ablation of cervical dysplasia. Sci Rep. 2021 Aug 19;11(1):16869.Full Text Link to Item
-
Roh J-W, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee J-S, Ram P, Coleman RL, Sood AK. Editor's Note: Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer. Clin Cancer Res. 2021 Aug 1;27(15):4449.Full Text Link to Item
-
Montes de Oca MK, Dotters-Katz SK, Kuller JA, Previs RA. Adnexal Masses in Pregnancy. Obstet Gynecol Surv. 2021 Jul;76(7):437–450.Full Text Link to Item
-
Puechl AM, Spinosa D, Berchuck A, Secord AA, Drury KE, Broadwater G, Wong J, Whitaker R, Devos N, Corcoran DL, Strickland KC, Previs RA. Molecular Classification to Prognosticate Response in Medically Managed Endometrial Cancers and Endometrial Intraepithelial Neoplasia. Cancers (Basel). 2021 Jun 7;13(11).Full Text Link to Item
-
Islam JY, Saraiya V, Previs RA, Akinyemiju T. Health Care Access Measures and Palliative Care Use by Race/Ethnicity among Metastatic Gynecological Cancer Patients in the United States. Int J Environ Res Public Health. 2021 Jun 4;18(11).Full Text Link to Item
-
Alholm Z, Spinosa D, Previs RA, Shuey SL, O’Malley DM, Randall L, Slomovitz B, Monk BJ. SARS-CoV-2 vaccination in gynecologic oncology. European Journal of Gynaecological Oncology. 2021 Apr 15;42(2):402–404.Full Text
-
Bailey CD, Previs R, Fellman BM, Zaid T, Huang M, Brown A, Enbaya A, Balakrishnan N, Broaddus RR, Bodurka DC, Soliman P, Fleming ND, Nick A, Sood AK, Westin SN. Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. Int J Gynecol Cancer. 2021 Feb;31(2):232–237.Full Text Link to Item
-
Islam JY, Deveaux A, Previs RA, Akinyemiju T. Racial and ethnic disparities in palliative care utilization among gynecological cancer patients. Gynecol Oncol. 2021 Feb;160(2):469–476.Full Text Link to Item
-
Islam JY, Deveaux A, Previs RA, Akinyemiju T. Racial disparities in palliative care utilization among metastatic gynecological cancer patients living at last follow-up: An analysis of the National Cancer Data Base. Data Brief. 2021 Feb;34:106705.Full Text Link to Item
-
Spinosa D, Acosta T, Wong J, Kurtovic K, Mewshaw J, Collins S, Kauff N, Havrilesky LJ, Strickland KC, Previs RA. Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative. Gynecol Oncol. 2021 Jan;160(1):169–174.Full Text Link to Item
-
Watson CH, Broadwater G, Wong J, Spinosa D, de Oca MKM, Datto M, Green M, Hubbard C, McKinney M, McCall SJ, Havrilesky LJ, Strickler JH, Berchuck A, Strickland KC, Previs RA. Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers. Target Oncol. 2021 Jan;16(1):109–118.Full Text Link to Item
-
Watson CH, Soo L, Davidson BA, Havrilesky LJ, Lee PS, McNally LJ, Previs RA, Secord AA, Berchuck A, Kauff ND. Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices. Int J Gynecol Cancer. 2020 Oct;30(10):1583–1588.Full Text Link to Item
-
Siamakpour-Reihani S, Cobb LP, Jiang C, Zhang D, Previs RA, Owzar K, Nixon AB, Alvarez Secord A. Differential expression of immune related genes in high-grade ovarian serous carcinoma. Gynecol Oncol. 2020 Mar;156(3):662–668.Full Text Link to Item
-
VanDusen KW, Eleswarpu S, Moretti EW, Devinney MJ, Crabtree DM, Laskowitz DT, Woldorff MG, Roberts KC, Whittle J, Browndyke JN, Cooter M, Rockhold FW, Anakwenze O, Bolognesi MP, Easley ME, Ferrandino MN, Jiranek WA, Berger M, MARBLE Study Investigators. The MARBLE Study Protocol: Modulating ApoE Signaling to Reduce Brain Inflammation, DeLirium, and PostopErative Cognitive Dysfunction. J Alzheimers Dis. 2020;75(4):1319–1328.Full Text Open Access Copy Link to Item
-
Previs RA. Becoming a surgeon-scientist: my transition from fellowship to faculty. Clin Adv Hematol Oncol. 2019 Dec;17(12):677–678.Link to Item
-
Armbruster SD, Previs R, Soliman PT, Westin SN, Fellman B, Jhingran A, Fleming ND. Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. Gynecol Oncol. 2019 Aug;154(2):328–332.Full Text Link to Item
-
Berger M, Oyeyemi D, Olurinde MO, Whitson HE, Weinhold KJ, Woldorff MG, Lipsitz LA, Moretti E, Giattino CM, Roberts KC, Zhou J, Bunning T, Ferrandino M, Scheri RP, Cooter M, Chan C, Cabeza R, Browndyke JN, Murdoch DM, Devinney MJ, Shaw LM, Cohen HJ, Mathew JP, INTUIT Investigators. The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction. J Am Geriatr Soc. 2019 Apr;67(4):794–798.Full Text Open Access Copy Link to Item
-
Davidson BA, Broadwater G, Crim A, Boccacio R, Bixel K, Backes F, Previs RA, Salinaro J, Salani R, Moore K, Secord AA. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2019 Mar;152(3):554–559.Full Text Link to Item
-
Previs RA, Secord AA. Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management. Obstet Gynecol Clin North Am. 2019 Mar;46(1):67–88.Full Text Link to Item
-
Kurnit KC, Previs RA, Soliman PT, Westin SN, Klopp AH, Fellman BM, Lu KH, Ramondetta LM, Fleming ND. Prognostic factors impacting survival in early stage uterine carcinosarcoma. Gynecol Oncol. 2019 Jan;152(1):31–37.Full Text Link to Item
-
Secord AA, Previs RA, Nixon AB. Cabozantinib in ovarian clear cell cancers: UnMET expectations. Gynecol Oncol. 2018 Jul;150(1):1–2.Full Text Link to Item
-
Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AK. Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res. 2018 Jun 15;78(12):3233–3242.Full Text Link to Item
-
Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AK. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther. 2018 Feb;17(2):464–473.Full Text Link to Item
-
Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15;23(22):7034–7046.Full Text Link to Item
-
Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Nov 14;8(57):96496–96505.Full Text Link to Item
-
Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Sood AK. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst. 2017 Jul 1;109(7).Full Text Link to Item
-
Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Jan 1;8(57):96496–96505.Full Text
-
Huang Y, Lichtenberger LM, Taylor M, Bottsford-Miller JN, Haemmerle M, Wagner MJ, Lyons Y, Pradeep S, Hu W, Previs RA, Hansen JM, Fang D, Dorniak PL, Filant J, Dial EJ, Shen F, Hatakeyama H, Sood AK. Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. Mol Cancer Ther. 2016 Dec;15(12):2894–2904.Full Text Link to Item
-
Previs RA, Sood AK, Mills GB, Westin SN. The rise of genomic profiling in ovarian cancer. Expert Rev Mol Diagn. 2016 Dec;16(12):1337–1351.Full Text Link to Item
-
Highley LL, Previs RA, Dotters-Katz SK, Brancazio LR, Grotegut CA. Cesarean delivery among women with prolonged labor induction. J Perinat Med. 2016 Oct 1;44(7):759–766.Full Text Link to Item
-
Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, Previs RA, Nagaraja AS, Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Zhang W, Lopez-Berestein G, Calin GA, Sood AK. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene. 2016 Aug 18;35(33):4312–4320.Full Text Link to Item
-
Whiting N, Hu J, Zacharias NM, Lokesh GLR, Volk DE, Menter DG, Rupaimoole R, Previs R, Sood AK, Bhattacharya P. Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer. J Med Imaging (Bellingham). 2016 Jul;3(3):036001.Full Text Link to Item
-
Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang X-Y, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Mol Cancer Ther. 2016 Jun;15(6):1344–1352.Full Text Link to Item
-
Nagaraja AS, Dorniak PL, Sadaoui NC, Kang Y, Lin T, Armaiz-Pena G, Wu SY, Rupaimoole R, Allen JK, Gharpure KM, Pradeep S, Zand B, Previs RA, Hansen JM, Ivan C, Rodriguez-Aguayo C, Yang P, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene. 2016 May 5;35(18):2390–2397.Full Text Link to Item
-
Kang Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA, Hansen JM, Rodriguez-Aguayo C, Ivan C, Ram P, Sehgal V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. Clin Cancer Res. 2016 Apr 1;22(7):1713–1724.Full Text Link to Item
-
Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK. Role of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst. 2016 Jan 26;108(6):djv426.Full Text Link to Item
-
Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NMZ, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Kovacs J, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AK. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Rep. 2015 Dec 22;13(11):2395–2402.Full Text Link to Item
-
Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Mol Cancer Ther. 2015 Dec;14(12):2677–2686.Full Text Link to Item
-
Fuh KC, Secord AA, Bevis KS, Huh W, ElNaggar A, Blansit K, Previs R, Tillmanns T, Kapp DS, Chan JK. Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. Gynecol Oncol. 2015 Dec;139(3):413–418.Full Text Link to Item
-
Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung M-C, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 2015 Nov 9;28(5):610–622.Full Text Link to Item
-
Matsuo K, Hasegawa K, Yoshino K, Murakami R, Hisamatsu T, Stone RL, Previs RA, Hansen JM, Ikeda Y, Miyara A, Hiramatsu K, Enomoto T, Fujiwara K, Matsumura N, Konishi I, Roman LD, Gabra H, Fotopoulou C, Sood AK. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. Eur J Cancer. 2015 Sep;51(14):1978–1988.Full Text Link to Item
-
Previs R, Leath CA, Coleman RL, Herzog TJ, Krivak TC, Brower SL, Tian C, Secord AA. Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. Gynecol Oncol. 2015 Aug;138(2):267–271.Full Text Link to Item
-
Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AK. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clin Cancer Res. 2015 Jul 15;21(14):3286–3297.Full Text Link to Item
-
Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali-Fehmi R, Coleman RL, Sood AK. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Mol Cancer Ther. 2015 Jun;14(6):1466–1475.Full Text Link to Item
-
Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, Aslan B, Del C Monroig P, Velazquez-Torres G, Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, Calin G, Sood AK, Lopez-Berestein G. Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clin Cancer Res. 2015 May 1;21(9):2127–2137.Full Text Link to Item
-
Previs RA, Coleman RL, Harris AL, Sood AK. Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res. 2015 Mar 1;21(5):955–961.Full Text Link to Item
-
Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JMG, Cole SW, Lutgendorf SK, Sood AK, Lopez-Berestein G. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget. 2015 Feb 28;6(6):4266–4273.Full Text Link to Item
-
Bottsford-Miller J, Choi H-J, Dalton HJ, Stone RL, Cho MS, Haemmerle M, Nick AM, Pradeep S, Zand B, Previs RA, Pecot CV, Crane EK, Hu W, Lutgendorf SK, Afshar-Kharghan V, Sood AK. Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clin Cancer Res. 2015 Feb 1;21(3):602–610.Full Text Link to Item
-
Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee J-S, Vivas-Mejia PE, Coleman RL, Sood AK. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res. 2015 Jan 15;21(2):448–459.Full Text Link to Item
-
Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee J-S, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15;74(12):3282–3293.Full Text Link to Item
-
Roh J-W, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee J-S, Ram P, Coleman RL, Sood AK. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer. Clin Cancer Res. 2014 May 15;20(10):2740–2750.Full Text Link to Item
-
Previs RA, Kilgore J, Craven R, Broadwater G, Bean S, Wobker S, DiFurio M, Bae-Jump V, Gehrig PA, Secord AA. Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer. Int J Gynecol Cancer. 2014 May;24(4):670–675.Full Text Link to Item
-
Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han H-D, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NAJ, Overwijk WW, Liu J, Lee J-S, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014 Mar 12;5:3459.Full Text Link to Item
-
Previs RA, Bevis KS, Huh W, Tillmanns T, Perry L, Moore K, Chapman J, McClung C, Kiet T, Java J, Chan J, Secord AA. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. Gynecol Oncol. 2014 Mar;132(3):531–536.Full Text Link to Item
-
Previs RA, Edwards JM, Secord AA, Nucci MR, Bentley RC, Hall AHS. Cystic fibrosis involving the cervix, mimicking a well-differentiated adenocarcinoma: a case report. Int J Gynecol Pathol. 2014 Jan;33(1):100–104.Full Text Link to Item
-
-
Book Sections
-
Spinosa D, Montes de Oca MK, Watson CH, Berchuck A, Previs RA. Endometrial cancer. Genomic and Precision Medicine: Oncology, Third Edition. 2022. p. 191–203.Full Text
-
Previs RA, Bodurka DC. Diagnosis and management of stage II endometrial cancer. Uterine Cancer: Diagnosis and Treatment. 2015. p. 293–305.Full Text
-
-
Conference Papers
-
Wong J, Gonzalez R, Albright B, Hayes T, Swartz A, Havrilesky LJ, Lee PS, Previs RA. Telemedicine and gynecologic oncology: caring for patients remotely during a global pandemic. Ajog Global Reports. 2022.Full Text
-
Montes de Oca MK, Howell EP, Spinosa D, Knochenhauer H, Peipert BJ, Severson E, Ramkissoon S, Akinyemiju TF, Previs RA. Diversity and transparency in gynecologic oncology clinical trials. Cancer Causes Control. 2022.Full Text Link to Item
-
-
- Teaching & Mentoring
-
Advising & Mentoring
-
Gynecologic oncology fellow mentor - 2019-present
Duke MS3 medical student mentor - 2019-present
OB/Gyn Coaching Program - 2018-present
OB/Gyn Resident Mentor for Resident Research Day - 2018-present
-
Gynecologic oncology fellow mentor - 2019-present
-
Teaching Activities
-
First-Year Engineering Design class, project mentor, fall 2021
Bootcamp: PostOp Care for MS4 students, 2021, 2022
Medical student bimonthly research group and lecture series, 2020, 2021
Grand Rounds Presentation: "ERAS for Gyencologic Surgery," 2019
Longitudinal integrative clerkship program preceptor for medical students, 2018--2022
Cased Base Learning group leader for OB/GYN medical students, spring 2018
Lectures in gynecologic oncology fellowship, obstetrics/gynecology and radiation oncology residency series, 2018-2022
-
First-Year Engineering Design class, project mentor, fall 2021
- Scholarly, Clinical, & Service Activities
-
Presentations & Appearances
- Hormonal Therapy for Inoperable Uterine Cancer. American Brachytherapy Society Webinar | Challenges in Gyn Brachytherapy Medically Inoperable Uterine Cancer. March 2022 2022
- Moderator for Uterine Cancer Session. The Society of Gynecologic Oncology 2022 Winter Meeting. February 2022 2022
- NRG Oncology Winter Virtual Symposium, Endocrine Therapy for Gynecologic and other Cancers: Many Targets, Many Indications, Virtual Presentation, Moderator. . February 2022 2022
- Hormonal therapy…a lost art?. The Society of Gynecologic Oncology 2022 Winter Meeting. January 2022 2022
- Chesapeake Bay Governor’s School for Marine and Environmental Science Career Day Presentation from an Oncologist. December 2021 2021
- Molecular classification of endometrial cancer and treatment implications. . Beijing Obstetrics and Gynecology Hospital (BOGH)’s 12th Annual Meeting. Capital Medical University, Beijing, China. November 2021 2021
- Distillation for Scientific Session II: Ovary. Mid-Atlantic Oncology Society 2021 Annual Meeting. October 2021 2021
- More than Alphabet Soup: Practical and Practice Changing Molecular Biology in Gynecologic Oncology . F. Bayard Carter Society 2021 Scientific Program . October 2021 2021
- Podcast: Primary Cytoreduction for Advanced Endometrial Cancer with Rebecca Previs and Benjamin Albright. International Journal of Gynecological Cancer Podcast series. July 2021 2021
- A discussion with Dr. Previs & Dr. Tewari on actively accruing GYN Clinical Trials. 2021 2021
- Advances in The Systemic Treatment of Cervical Cancer Through Clinical Trials. 2021 2021
- DQN/DCN Presentation - Gynecologic Cancer Prevention. 2021 2021
- Decision-IQ: A Case-Based Overview of Screening for Lynch Syndrome in a Patient with Uterine Cancer. 2021 2021
- Moderator of Focused Plenary VI: Pre-clinical innovation: Exploring new horizons at the 2021 Annual Meeting of the Society of Gynecologic Oncologists. 2021 2021
- Lab Life. Felix Rutledge Society (Cancelled due to COVID-19 pandemic). May 8, 2020 2020
- NRG Oncology Social Media Workshop. NRG Oncology. January 10, 2020 2020
- ProMisE into practice: Translational and quality improvement projects in molecularly characterized uterine cancers. Ponce Medical School. October 25, 2019 2019
- Twitter 101 . NRG Oncology. February 8, 2019 2019
- Immune modulation of CaMKK2 in the ovarian tumor microenvironment. Felix Rutledge Society Annual Meeting. October 18, 2018 2018
- Advances in the Management of GYN Malignancies - Highlights from 2018. Duke Cancer Review. July 2018 2018
- Two to tango: Biological activity and companion predictive markers for a novel dual AKT and P70S6K inhibitor in ovarian and uterine malignancies. Seminars in Women's Cancer. March 22, 2018 2018
-
Outreach & Engaged Scholarship
-
Service to the Profession
-
Service to Duke
-
Academic & Administrative Activities
-
Duke Committees
DCI Rural Disparities Subgroup 2022 to present
DCI Patient Advisory Council for Inclusive Research 2022 to present
DCI Focus Group on Adoptive T-cell Therapies 2022 to present
DCI Community Outreach, Engagement, and Equity Steering Committee 2021 to present
EMPOWER Women in Oncology Committee member - 2019 to present
Duke Center for Brain and Spine Metastasis Gynecologic Oncology Champion - 2019 to present
Duke CCPS Neuro Complications Working Group - 2019 to present
Center for Cancer Immunology disease site champion - 2019 to present
Duke Institutional Review Board Committee member - 2018 to present
Cancer Protocol Committee member - 2018 to present
Department On-boarding Task Force Committee – 2018-2019
OB/GYN Residency Admissions Committee member – 2017-2019
National Committee
NRG Oncology Translational Science Committee – 2022 to present
Society for Gynecologic Oncology Program Committee - 2020-2021
NRG Oncology Developmental Therapeutics/Phase 1 - 2019 to present
NRG Oncology Communications Committee - 2019 to present
GOG-F Communications Committee - 2019 to present
Endometrial Cancer Molecularly Targeted Therapy Consortium, Publications Committee - 2019 to present
NRG Oncology Young Investigator Committee 2017 to presentJournal Reviewer
AJOB
BMC Cancer
Cancer
Cancers
Cells
Endocrine-Related Cancer
Frontiers Oncology
Gyn Onc
Gyn Onc Case Reports (editorial board)
IGCS
Journal of Minimally Invasive Gynecology
Molecular Therapy - Oncolytics
Oncology
Targeted Oncology
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.
